HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Yamamoto, T. Articles by Sugita, H. Search for Related Content PubMed PubMed Citation Articles by Yamamoto, T. Articles by Sugita, H.

Antifilamin, antivinculin, and antitropomyosin antibodies in myasthenia gravis

National Institute of Neuroscience (Drs. Yamamoto and Sugita), NCNP, and the Department of Neurology (Drs. Yamamoto and Sato), Faculty of Medicine, Juntendo University, Tokyo, Japan.

Antifilamin, antivinculin, and antitropomyosin antibody activities were investigated in sera from 43 patients with myasthenia gravis (MG). Antifilamin and antivinculin antibody activities are significantly higher in MG patients compared with normal controls and patients with Duchenne muscular dystrophy (DMD), Parkinson's disease, and spinocerebellar degeneration. The antifilamin antibody was highly positive (100%) in ocular myasthenia. Antitropomyosin antibody activity was similar to that in DMD patients. No correlation was observed between these antibody activities and the anti-acetylcholine receptor antibody titers, the duration of the disease, and thymic pathology.

Address correspondence and reprint requests to Dr. Yamamoto, Department of Neurology, Faculty of Medicine, Juntendo University, 2–1–1 Hongo, Bunkyo-ku, Tokyo 112, Japan.

Received July 24, 1986. Accepted for publication in final form December 12, 1986.